IMPORTANT:

Investors should note that all investments involve risks (including the possibility of loss of the capital invested), prices of fund shares may go up as well as down and past performance is not indicative of future performance. Investors should read the Company's Prospectus (including the Product Key Facts Statement of the Sub-Fund ("KFS") and the full text of the risk factors stated therein) in detail before making any investment decision.

The Stock Exchange of Hong Kong Limited (the "SEHK"), Hong Kong Securities Clearing Company Limited ("HKSCC") and the Securities and Futures Commission (the "SFC") take no responsibility for the contents of this document, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this document.

SFC authorisation is not a recommendation or endorsement of the Sub-Fund nor does it guarantee the commercial merits of the Sub-Fund or its performance. It does not mean the Sub-Fund is suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors.

This document is important and requires your immediate attention. If you are in doubt about the contents of this document, you should seek independent professional financial advice.

CSOP ETF Series OFC
(the "**Company**")

(a Hong Kong public umbrella open-ended fund company with variable capital, limited liability and segregated liability between sub-funds and authorized under section 104 of the Securities and Futures Ordinance (Cap. 571) of Hong Kong)

CSOP CHINA HEALTHCARE DISRUPTION INDEX ETF

(the "Sub-Fund")
Stock Code: 3174

Announcement

Change of Underlying Index, Name and Short Name of the Sub-Fund

CSOP Asset Management Limited (the "**Manager**"), hereby announces that, from 15 September 2025 (the "**Effective Date**"), the underlying index of the Sub-Fund will change from the Solactive China Healthcare Disruption Index to the Hang Seng Biotech Index. The investment objective and investment strategy of the Sub-Fund will be amended to reflect the change of the underlying index. In particular, the Sub-Fund's investment strategy will be changed to reflect that the Manager intends to adopt a combination of physical representative sampling and synthetic representative sampling strategy. Consequently, the name of the Sub-Fund will change to CSOP Hang Seng Biotech ETF.

In addition, from the Effective Date, the cap on ongoing charges over a year figure ("**OCF Cap**") for the Sub-Fund at 3.00% will be removed.

Investors should exercise caution in dealing with the shares of the Sub-Fund.

1. Change of Underlying Index

Currently, the underlying index of the Sub-Fund is the Solactive China Healthcare Disruption Index (the "**Existing Index**"). With effect from the Effective Date, the underlying index of the Sub-Fund will be changed

to the Hang Seng Biotech Index (the "**New Index**"). The rebalancing to the constituents of the New Index is anticipated to take place over a period of 5 trading days starting on the Effective Date. Please refer to section E below for more information on the rebalancing process.

A. Information about the New Index and comparison between the Existing Index and the New Index

Please refer to Appendix 1 to this Announcement for a summary of the information about the New Index. A comparison of the key features of the Existing Index and the New Index are summarised in the table below:

	Solactive China Healthcare Disruption Index (Existing Index)	**Hang Seng Biotech Index (New Index)**
Index Provider	Solactive AG	Hang Seng Indexes Company Limited
Index Universe	- Listed on the Hong Kong Stock Exchange - Headquartered in mainland China / Hong Kong / Taiwan / Macau - Minimum average daily value traded of at least USD 1,000,000 over the last 2 months - Total market capitalization of at least HKD 3,000,000,000	Constituents of Hang Seng Composite Index which are eligible for Southbound trading under the Stock Connect Scheme ("***Southbound Stock Connect***").
Market Capitalisation	HKD 908.67 billion (as of 30 June 2025)	Estimated to be HKD 694.76 billion (as of 8 September 2025) Note: the index methodology of the New Index will be updated, with constituent updates implemented on 8 September 2025. Hence, the market capitalisation of the New Index as of 8 September 2025 is estimated based on the market capitalisation (as of 30 June 2025) of the revamped index constituents which are provided by the Index Provider.
Number of Constituents	42	Fixed at 30


B. Change to the investment objective and strategy of the Sub-Fund

The investment objective and investment strategy of the Sub-Fund will be amended to reflect the change of the underlying index. In particular, the Sub-Fund's investment strategy will be changed to reflect that the Manager intends to adopt a combination of physical representative sampling and synthetic representative sampling strategy, as summarised below:

Existing investment objective and strategy	**New investment objective and strategy**
Objective The investment objective of the Sub-Fund is to provide investment results that, before deduction of fees and expenses, closely correspond to the performance of the Index, namely, Solactive China Healthcare Disruption Index (the "**Index**"). There is no assurance that the Sub-Fund will achieve its investment objective. ***Investment Strategy***	***Objective*** The investment objective of the Sub-Fund is to provide investment results that, before deduction of fees and expenses, closely correspond to the performance of the Index, namely, Hang Seng Biotech Index (the "**Index**"). There is no assurance that the Sub-Fund will achieve its investment objective. ***Investment Strategy***

The Sub-Fund is a physical ETF and invests primarily in Hong Kong listed companies that have business operations in various innovative fields such as biotechnology and biopharmaceuticals in the healthcare sector in mainland China, Hong Kong, Taiwan and Macau. The Sub-Fund is denominated in HKD. In order to achieve the investment objective, the Sub-Fund primarily uses a physical representative sampling strategy through investing up to 100% of its NAV in a representative portfolio of securities that collectively has a high correlation with the Index, but whose constituents may or may not themselves be constituents of the Index ("**Index Securities**").	In order to achieve the investment objective of the Sub-Fund, the Manager intends to adopt a combination of physical representative sampling and synthetic representative sampling strategy. The Sub-Fund will (i) primarily use a physical representative sampling strategy by investing 50% to 100% of its Net Asset Value in a representative sample whose performance is closely correlated with the Index; and (ii) where the Manager believes such investments are beneficial to the Sub-Fund and will help the Sub-Fund achieve its investment objective, use a synthetic representative sampling strategy as an ancillary strategy by investing up to 50% of its Net Asset Value in FDIs, which will include Futures Contracts and Swaps. *Physical representative sampling sub-strategy* The Sub-Fund primarily uses a physical representative sampling strategy by investing 50% to 100% of its Net Asset Value in (a) a representative sample whose performance is closely correlated with the Index, but whose constituents may or may not themselves be constituents of the Index ("**Index Securities**"); and (b) other collective investment schemes ("**CIS**"). "CIS" means an exchange traded fund and/or an unlisted index tracking fund that tracks an index that has a high correlation with the Index. The Sub-Fund's ability to invest in other CIS may not exceed 10% of the Net Asset Value of the Sub-Fund and the Sub-Fund will not hold more than 10% of any units issued by any single CIS pursuant to the requirement of the Code. *Synthetic representative sampling sub-strategy* The Sub-Fund's synthetic representative sampling strategy will involve investing up to 50% of its Net Asset Value in FDIs, which include Futures Contracts and Swaps. The Futures Contracts may be invested by the Sub-Fund will be index futures to manage exposure to the constituents of the Index, if available. The Swaps which may be invested by the Sub-Fund will be funded total return Swap transaction(s) whereby the Sub-Fund will pass on the relevant portion of cash to the Swap Counterparty(ies) and in return the Swap Counterparty(ies) will provide the Sub-Fund with an exposure to the economic gain/loss in the performance of the relevant Securities (net of indirect costs). The expected proportion of the Sub-Fund's Net Asset Value subject to investments in Futures Contracts and Swaps will not exceed 20% and 50% of its Net Asset Value, respectively, and in any event the Sub-Fund's aggregate investments in FDIs will be limited to

	50% of its Net Asset Value. Exposure of the Sub-Fund to the Index Securities (either through direct investment or FDIs) will be in substantially the same weightings (i.e. proportions) as these Index Securities have in the Index. The Sub-Fund will bear the Swap fees, which includes all costs associated with Swap transactions and are subject to the discussion and consensus between the Manager and the Swap counterparty based on the actual market circumstances on a case-by-case basis. The Swap fees represent the brokerage commission and the Swap Counterparty's cost of financing the underlying hedge. Currently, the Swap fees are expected to range from -1.00% to 1.00%* per annum of the Swap notional amount (i.e. from -1.00% to 1.00%* per annum of the Sub-Fund's Net Asset Value). This is a best estimate only and the actual Swap fees may deviate from the aforesaid estimate depending on actual market conditions. In extreme market conditions and exceptional circumstances, the brokerage commission and the Swap Counterparty's costs of financing the underlying hedge may increase significantly and in return increase the Swap fees. When the actual Swap fee level exceed the disclosed level, the Manager will issue notice to the investors. The Sub-Fund shall bear the Swap fees (including any costs associated with the entering into, or unwinding or maintenance of, any hedging arrangements in respect of such Swaps). Swap fees are accrued daily and spread out over the month. The maximum unwinding fee payable by the Sub-Fund is 0.50%* per transaction on the notional amount of the Swap unwound. The Swap fees will be disclosed in the interim and annual financial reports of the Sub-Fund. The Swap fees will be borne by the Sub-Fund and hence may have an adverse impact on the Net Asset Value and the performance of the Sub-Fund, and may result in higher tracking error. * A positive figure denotes the fee that the Sub-Fund pays to the Swap Counterparties. A negative figure denotes the fee that the Swap Counterparties pay to the Sub-Fund.

	The diagram below shows the representative sampling investment strategies of the Sub-Fund:  […] Other than as set out above, the Sub-Fund may invest in FDIs for hedging purposes.

Save for the changes mentioned above, there will be no change to other ancillary investments of the Sub-Fund and Securities Lending Transactions, Sale and Repurchase Transactions, Reverse Repurchase Transactions and other similar over-the-counter transactions of the Sub-Fund.

C. Change of name and short name of the Sub-Fund

The name of the Sub-Fund will also be changed to CSOP Hang Seng Biotech ETF to reflect the change of underlying index. Accordingly, the short stock name of the Sub-Fund will also be changed from the Effective Date as follows:

	As at the date of this Announcement	**From the Effective Date onwards**
English name	CSOP China Healthcare Disruption Index ETF	CSOP Hang Seng Biotech ETF
Chinese name	南方東英中國醫療健康革新指數 ETF	南方東英恒生生物科技 ETF
English short stock name	CSOP HEALTHCARE	CSOP HSBIOTECH
English short stock name	南方醫療健康	南方恒生生科

D. Rationale

The New Index focuses on the biotech theme, whereas the Existing Index focuses on the healthcare theme. The Manager believes that the New Index aligns more closely with current industry trends and investor interests, making it a strategically advantageous choice for the Sub-Fund and its Shareholders. The Manager believes that the change is in the best interest of the Sub-Fund and investors.

E. Rebalancing process

The rebalancing of assets held by the Sub-Fund from constituents of the Existing Index to constituents of the New Index is anticipated to take place over a period of 5 trading days starting on the Effective Date, ending on 19 September 2025 at the latest (the "**Rebalancing Period**").

During the Rebalancing Period, the tracking error and tracking difference of the Sub-Fund may be higher than its historical level. Investors should note that after the Rebalancing Period, there is no guarantee

that the tracking error and tracking difference of the Sub-Fund will be similar to that before the change in underlying index. Furthermore, although there is a high degree of correlation between the Existing Index and New Index, the Manager considers there is a risk that the tracking error and tracking difference of the Sub-Fund during the Rebalancing Period may increase. Investors who deal with shares of the Sub-Fund during the Rebalancing Period should exercise caution.

The Manager does not expect that the rebalancing will have any material impact on the market.

F. Risk Factors

As mentioned above, there may be risks associated with the rebalancing process. In addition, as a result of the changes, the Sub-Fund will be subject to risks associated with medicine distribution companies and synthetic representative sampling risk (described below) and the Sub-Fund will no longer be subject to the "*Disruption/innovative healthcare sector risk*".

Risks associated with medicine distribution companies
The investments of the Sub-Fund include medicine distribution companies. Prices of products of medicine distribution companies may be subject to pricing regulation and competition. Medicine distribution companies depend on goodwill and reputation which may be impacted by factors including counterfeit products and efficacy or side effects of products. Medicine distribution companies are also subject to risks of rapid changes in product life cycles and inventory risk, as well as supply chain risk and disruption to storage facilities as a result of various factors including weather conditions, natural disasters or other unanticipated catastrophic events. All these may have impact on the business and/or profitability of medicine distribution companies in which the Sub-Fund invests and therefore may adversely affect the Net Asset Value of the Sub-Fund.

Synthetic representative sampling risk
The Manager seeks to mitigate the counterparty risks by fully collateralising all counterparty exposures. There is a risk that the value of the collateral may be substantially lower than the amount secured and so the Sub-Fund may suffer significant losses. Any loss would result in a reduction in the Net Asset Value of the Sub-Fund and impair the ability of the Sub-Fund to achieve its investment objective to track the Index.

In the case of funded Swaps, the Sub-Fund may suffer significant losses if the counterparty fails to perform its obligations under the funded Swap. The value of the collateral assets may be affected by market events and may diverge substantially from the performance of the Index, which may cause the Sub-Fund's exposure to the Swap Counterparty to be under-collateralised and therefore result in significant losses.

Save for the above, the Sub-Fund will generally be subject to the same risks to which it is currently exposed, with amendments resulting from change of underlying index summarised below:

Risks associated with biotech companies

The investments of the Sub-Fund ~~in the healthcare sector may~~ include biotech companies and hence subject to the risks associated with biotech companies. Biotech companies invest heavily in research and development which may not necessarily lead to commercially successful products. The costs associated with and time needed for developing new products can be significant, and the results are unpredictable. Any failure in research and development may have a material adverse impact on a biotech company's ongoing prospect. Biotech companies can be significantly affected by technological change and newly developed products may be susceptible to product obsolescence due to intense competition from new products and less costly generic products.

[…]

Risks associated with pharmaceutical and medical devices <u>& supplies</u> companies

The investments of the Sub-Fund ~~in the healthcare sector may also~~ include pharmaceutical and medical devices <u>& supplies</u> companies. Pharmaceutical and medical devices <u>& supplies</u> companies are heavily dependent on patent protection. The expiration of patents may adversely affect the profitability of the companies. Many new products are subject to regulatory approval, the process of which can be long and costly and approved products are susceptible to obsolescence. Certain

pharmaceutical and medical devices & supplies companies may allocate greater than usual financial resources to research and product development and experience above-average price movements associated with the perceived prospects of success of the research and development programs. Pharmaceutical and medical devices & supplies companies are also subject to heavy competitive forces that may make it difficult to raise prices. All these may have impact on the business and/or profitability of pharmaceutical and medical devices & supplies companies in which the Sub-Fund invests and therefore may adversely affect the NAV of the Sub-Fund.

Concentration risk

The Index is subject to concentration risk as a result of tracking the performance of companies listed on the SEHK in a particular sector (i.e. "Pharmaceuticals", "Biotechnology", "Medicine Distribution" and "Medical Devices & Supplies"). Although the Index does not have a particular geographical concentration by virtue of its methodology and constituents selection criteria, the Index constituents may from time to time be concentrated in Hong Kong and PRC companies. The NAV of the Sub-Fund is therefore likely to be more volatile than a more broad-based fund, such as a global or regional fund tracking other broad-based stock indices, as the Index is more susceptible to fluctuations in value resulting from adverse conditions in a single market and sector.

~~Due to the concentration of the Index in the companies focusing on innovative fields in the healthcare sector, which is characterised by relatively higher volatility in price performance when compared to other economic sectors, the performance of the Index may be more volatile when compared to other broad-based stock indices.~~

~~Also, the Index is subject to geographical concentration risks as a result of tracking the performance of primarily the Hong Kong listed companies that have business operations in the field of healthcare sector in mainland China, Hong Kong, Taiwan and Macau. The value of the Sub-Fund may be more susceptible to adverse economic, political, policy, foreign exchange, liquidity, tax, legal or regulatory event affecting the Hong Kong market and places where these companies have business operations including mainland China, Taiwan and Macau.~~

2. Removal of cap on ongoing charges figure of the Sub-Fund

Currently, the OCF Cap of the Sub-Fund in the KFS dated 24 April 2025 is 3.00% per annum. In order to enhance operational flexibility and adaptability of the Sub-Fund, the Manager wishes to remove the OCF Cap. For the avoidance of doubt, there is no change in the ongoing charges figures notwithstanding the removal of the OCF Cap.

3. Impact on the Sub-Fund

The changes described in this Announcement do not require Shareholders' approval.

The Manager believes that the changes described in this Announcement will not materially prejudice the existing investors' rights or interests.

Other than the changes as described above, there is no change to the operation and/or manner in which the Sub-Fund is being managed, nor will there be any adverse effect on existing investors as a result of the change of the underlying index. Other than the removal of OCF Cap as described above, there is no change in the fee level or cost in managing the Sub-Fund following the implementation of the above changes.

As a result of the change in underlying index, objective and investment strategy of the Sub-Fund, past performance of the Sub-Fund prior to the Effective Date is achieved under circumstances which will no longer apply from the Effective Date. Investors should exercise caution when considering the past performance of the Sub-Fund prior to the Effective Date.

There will not be any material changes or increase in the overall risk profile of the Sub-Fund following the removal of OCF Cap. The Manager does not expect a substantive change to the ongoing charges figure and tracking difference figure of the Sub-Fund. The figures for the year ended 31 December 2024 are currently disclosed in the KFS. The Manager will monitor the ongoing charges and tracking difference and, if necessary, update the figures in the KFS, in accordance with the relevant SFC guidance.

Costs associated with the changes will be borne by the Sub-Fund. These costs are estimated to be no more than HKD120,000. These costs are not expected to be material to the Sub-Fund, and hence are not expected to pose any material impact to the NAV of the Sub-Fund nor any significant adverse impact to Shareholders.

The transaction costs (e.g. brokerage fees, stamp duties, taxes, charges paid to relevant stock exchanges) which may arise in relation to the rebalancing process (as described above at section E under "1. Change of Underlying Index" of this announcement) will be borne by the Sub-Fund and may vary subject to factors including portfolio holdings at the time of the rebalancing, the prevailing liquidity and volatility levels in the market, and the time taken to reposition underlying investments.

4. General

Unless otherwise stated, capitalised terms in this Announcement have the same meanings as defined in the Prospectus.

The Prospectus and the KFS will be updated to reflect the above changes and consequential changes, and will be available from the Manager's website at www.csopasset.com (this website has not been reviewed by the SFC) and the HKEX's website at www.hkexnews.hk on or around the Effective Date.

If you have any queries or require further information in relation to any aspect of this Announcement, please refer to http://www.csopasset.com/en/home (this website has not been reviewed by the SFC) or contact our Customer Service Hotline at (852) 3406 5688 or at 2801-2803, Two Exchange Square, 8 Connaught Place, Central, Hong Kong.

By Order of the Board
CSOP Asset Management Limited
Chief Executive Officer
Ding Chen

15 August 2025

As of the date of this Announcement, the board of directors of the Manager comprises 7 Directors namely, Mr. Zhou Yi, Ms. Chen Li, Mr. Yang Xiaosong, Mr. Cai Zhongping, Ms. Ding Chen, Mr. Wang Qin and Mr. Zhang Huachen.

Appendix 1

Summary of information about the New Index

The New Index is a net total return, free float adjusted market capitalisation weighted index with a 10% cap on individual stocks. It reflects the overall performance of the 30 largest biotech companies which are constituents of the Hang Seng Composite Index that are eligible for trading under the Stock Connect Scheme, that are classified as "Pharmaceuticals", "Biotechnology", "Medicine Distribution" and "Medical Devices & Supplies" in the Hang Seng Industry Classification System. The free float adjusted market capitalisation of individual stocks mainly engaged in "Medicine Distribution" will be discounted by 50% in the weighting calculation. A net total return index reflects the reinvestment of dividends or distributions, after deduction of any withholding tax. The New Index is denominated in HKD.

The New Index was launched on 16 December 2019 and had a base level of 10,000 on 31 December 2013.

Index Provider

The New Index is compiled and managed by Hang Seng Indexes Company Limited ("the "**Index Provider**"). The Manager (and each of its Connected Persons) are independent of the Index Provider.

Index Universe

The universe of securities of the New Index includes securities of companies which are constituents of Hang Seng Composite Index which are eligible for Southbound Stock Connect.

Eligibility Criteria

A security is eligible for constituent selection if it fulfils the following requirements:

1. Sector Requirements: Classified in one of the following industries in the Hang Seng Industry Classification System: "Pharmaceuticals", "Biotechnology", "Medicine Distribution" and "Medical Devices & Supplies".

2. Turnover Requirements: To pass the monthly turnover test if it attains a minimum velocity of 0.1% in that month (details of the velocity test as described in the Index Methodology General Guide published by the Index Provider).

   For each security, its turnover velocity in each of the past 12 months is calculated using the following formula:

$$\text{Velocity} = \frac{\text{Median of Daily Traded Shares in Specific Calendar Month}}{\text{Freefloat- adjusted Issued Shares at Month - end}}$$

   For the denominator used in velocity calculation, free float-adjusted issued shares at the end of each month is used.

   (1) For new constituents, a security should fulfil the following criteria:

   (a) velocity is a minimum of 0.1% for at least 10 out of the past 12 months, and

   (b) velocity is a minimum of 0.1% in for the latest three months.

   (2) For existing constituents, a security should fulfil the following criteria:

   (a) velocity is a minimum of 0.1% for at least 10 out of the past 12 months

   (b) if a constituent fails to meet the turnover requirement as mentioned in (a), a supplementary turnover test will be applied for those months in which its velocity was less than 0.1%:

   i. calculate the monthly aggregate turnover of the constituent;

ii. if the monthly aggregate turnover is among the top 90th percentile of the total market*, the constituent passes the monthly turnover test for that month.

(c) the constituent will be regarded as meeting the turnover requirement if (a) is fulfilled after applying (b) as a supplementary test.

* Total market includes securities in the universe of the Hang Seng Composite Index.

(3) For a security with a trading history of less than 12 months, or a security which has been suspended for any complete month(s), or a security that has transferred from the Growth Enterprise Market of the SEHK to the Main Board of the SEHK in the past 12 months before the review data cut-off date, the following requirements replace those in sections (1) and (2)

Trading Record	Measurements^
< 6 months	attain a minimum velocity of 0.1% for all trading months
≥ 6 months	(1) no more than one month in which security has failed to attain a velocity of at least 0.1% AND 2) attained 0.1% for the latest three months if it is not an existing constituent

^ For existing constituents, the supplementary turnover test as described in section (2) (b) also applies.

Constituent Selection

Selection Criteria

The top 30 securities with the highest MV Rank (as described below) will be selected as constituents.

The market value ("MV") of eligible securities will be used for ranking. It does not include other listed share classes of the same company. For example, MV of an H-shares security is calculated only based on the H-shares.

The MV of a security refers to the average daily market value of the past 12 months of any review period excluding suspended trading day(s). For securities with a listing history of less than 12 months, the MV refers to the average of the past trading days since the securities listed.

The MV will be sorted in descending order to get the MV Rank.

Buffer Zone

Existing constituents ranked lower than 36th will be removed from the New Index, while non-constituents ranked 24th or above will be included;

Securities will be added or excluded according to their MV Rank to maintain the number of constituents at 30.

Southbound Stock Connect Eligibility

Constituent eligibility under Southbound Stock Connect will be reviewed on a quarterly basis. Existing constituent(s) that are ineligible for Southbound Stock Connect (outside regular index review) will be removed without any replacement unless otherwise stated.

Calculation of Index

$$Current\ Index = \frac{\sum(P_t \times IS \times FAF \times CF \times AF)}{\sum(P_{t-1} \times IS \times FAF \times CF \times AF)} \times Yesterday's\ Closing\ In$$

P_t	:	Current Price at Day t
P_{t-1}	:	Closing Price at Day (t-1)
IS	:	Issued Shares
FAF	:	Freefloat Adjusted Factor, which is between 0 and 1
CF	:	Capping Factor, which is between 0 and 1
AF	:	Adjustment Factor

Index Reviews

The Index Provider undertakes regular quarterly reviews of the index constituents with data cut-off dates of end of March, June, September and December each year.

Quarterly reviews are normally completed within eight weeks after the data cut-off dates. Constituent changes, after the quarterly reviews, will be effective on the next trading day after the first Friday of June, September, December and March for the quarterly reviews conducted with the data cut-off dates at the end of March, June, September and December respectively. If the Friday falls on a public holiday, the effective date will be postponed to the next Friday (subject to the Index Provider's final decision). Under normal circumstances, five trading days' notice will be given for any constituent changes before the effective date.

The outgoing constituent will be replaced by the highest ranked candidate from the last regular review.

Index Securities

The list of the constituents of the New Index, their respective weightings, additional information and other important news of the New Index can be obtained from the website of the Index Provider at https://www.hsi.com.hk/eng/indexes/all-indexes/hshkbio (this website has not been reviewed by the SFC).

Index Codes

Bloomberg Code: HSBION
Refinitiv Code: .HSBION